These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 30608548)
21. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Basali D; Chakraborty R; Rybicki L; Rosko N; Reed J; Karam M; Schlueter K; Dysert H; Kalaycio M; Valent J Br J Haematol; 2020 Jun; 189(6):1136-1140. PubMed ID: 32012228 [TBL] [Abstract][Full Text] [Related]
22. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994 [TBL] [Abstract][Full Text] [Related]
23. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Muchtar E; Dispenzieri A; Kumar SK; Ketterling RP; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA Leukemia; 2017 Jul; 31(7):1562-1569. PubMed ID: 27904139 [TBL] [Abstract][Full Text] [Related]
24. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance. Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231 [TBL] [Abstract][Full Text] [Related]
25. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114 [No Abstract] [Full Text] [Related]
28. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Feyler S; O'Connor SJ; Rawstron AC; Subash C; Ross FM; Pratt G; Drayson MT; Ashcroft J; Cook G; Owen RG Br J Haematol; 2008 Mar; 140(5):547-51. PubMed ID: 18275432 [TBL] [Abstract][Full Text] [Related]
29. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Visram A; Vachon C; Baughn LB; Larson D; Smadbeck J; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S Leukemia; 2022 Apr; 36(4):1058-1065. PubMed ID: 34764424 [TBL] [Abstract][Full Text] [Related]
30. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations. Ji M; Jang S; Lee JH; Seo EJ Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601 [No Abstract] [Full Text] [Related]
31. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Gran C; Uttervall K; Borg Bruchfeld J; Wallblom A; Alici E; Gahrton G; Nahi H Eur J Haematol; 2019 Dec; 103(6):588-596. PubMed ID: 31487754 [TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis]. Mao XH; Deng SH; Sui WW; Fu MW; Liu JH; Fan HS; Zou DH; Zhao YZ; Qiu LG; An G Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):812-818. PubMed ID: 34105477 [TBL] [Abstract][Full Text] [Related]
33. The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. Vekemans MC; Lemmens H; Delforge M; Doyen C; Pierre P; Demuynck H; Bries G; Lemmens J; Meeus P; Straetmans N; Bauwens D; Vidrequin S; Rack K; Vandenberghe P; Wlodarska I; Michaux L Br J Haematol; 2010 Jun; 149(6):901-4. PubMed ID: 20148877 [No Abstract] [Full Text] [Related]
34. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma. Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268 [TBL] [Abstract][Full Text] [Related]
35. Comparing neuropathy in multiple myeloma and AL amyloidosis. Ballegaard M; Nelson LM; Gimsing P J Peripher Nerv Syst; 2021 Mar; 26(1):75-82. PubMed ID: 33368817 [TBL] [Abstract][Full Text] [Related]
36. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Perfetti V; Coluccia AM; Intini D; Malgeri U; Vignarelli MC; Casarini S; Merlini G; Neri A Am J Pathol; 2001 May; 158(5):1599-603. PubMed ID: 11337357 [TBL] [Abstract][Full Text] [Related]
38. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. Bal S; Giri S; Godby KN; Costa LJ Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783 [No Abstract] [Full Text] [Related]
39. Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Liebisch P; Scheck D; Erné SA; Wellmann A; Wendl C; Janczik S; Kolmus S; Kröber A; Einsele H; Straka C; Goldschmidt H; Benner A; Stilgenbauer S; Döhner H Genes Chromosomes Cancer; 2005 Jan; 42(1):78-81. PubMed ID: 15390182 [TBL] [Abstract][Full Text] [Related]
40. One translocation for 2 lymphoid neoplasms. Aussedat G; Baseggio L Blood; 2019 Jan; 133(2):180. PubMed ID: 30630847 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]